The Risk of Rheumatoid Arthritis in Patient with Type 2 Diabetes Mellitus Receiving DPP4 Inhibitors

Dipeptidyl peptidase-4 (DPP4) could be a transmembrane compound protein that encompasses a perform within the immunologic response. It additionally referred to as CD26, DPP4 inhibitors (DPP4i) are oral glucose-lowering drug for type two diabetes mellitus (T2DM).

This study aim to measure the risk of incident rheumatoid arthritis (RA) associated with DPP4i in patients with T2DM.

A 42-years-old male with history of RA presented to the outpatient due to hand tingling that was worse in the mornings. He also complained of excessive thirst, fnding himself drinking more water than usual and waking up in the night to urinate. There was no vomiting or nausea and no other symptoms. He did report feeling hungry. He had no family history of diabetes, and reported taking his medication for RA every day. The differential diagnosis for her thirst included dehydration, psychogenic polydipsia, diabetes mellitus, diabetes insipidus, and anxiety. The patient had normal vital signs and was well appearing; labs were ordered for him: labs revealed a FBG level of 215 mg/dL, PPG level of 265 mg/dl. Normal renal function tests and normal other investigations. He started combination therapy between DPP4 inhibitors and metformin.